Willda Met 50/1000 Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which in turn stimulate insulin secretion and inhibit glucagon release in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Willda Met 50/1000 is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient. It is important to monitor renal function prior to initiation and periodically during treatment due to the risk of metformin-associated lactic acidosis in patients with impaired renal function. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia risk is generally low but may increase when combined with other antidiabetic agents. This combination therapy should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.